---
title: "Faeth Therapeutics CEO Anand Kiran Parikh acquires $55,458.56 in common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290748010.md"
description: "Faeth Therapeutics CEO Anand Kiran Parikh increased his direct common stock stake to 817,699 shares. The filing details the purchase of 2,806 shares at $19.76 and the exercise of options for 53,465 shares at $1.16."
datetime: "2026-06-24T22:56:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290748010.md)
  - [en](https://longbridge.com/en/news/290748010.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290748010.md)
---

# Faeth Therapeutics CEO Anand Kiran Parikh acquires $55,458.56 in common shares

-   Faeth Therapeutics President and CEO Anand Kiran Parikh reported an increase in his direct common stock stake to 817,699 shares. \* The filing shows 2,806 shares bought at USD 19.76. \* It also reflects option exercises for 53,465 shares at USD 1.16. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002111813-26-000010), on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [FTH.US](https://longbridge.com/en/quote/FTH.US.md)

## Related News & Research

- [Faeth Therapeutics Adopts Performance-Based Stock Option Plan](https://longbridge.com/en/news/293674074.md)
- [Faeth Therapeutics grants new-hire stock options for 25,500 shares at $28.19 each](https://longbridge.com/en/news/293659677.md)
- [Faeth Therapeutics grants performance options to Anand Parikh, Christopher Gerry and Josiah Craver](https://longbridge.com/en/news/293670210.md)
- [ProQR Therapeutics director Bart Filius buys $257,925 of common shares](https://longbridge.com/en/news/293337504.md)
- [Rein Therapeutics holds annual shareholder meeting](https://longbridge.com/en/news/293381390.md)